Piper Sandler Starts Coverage on Climb Bio with Bullish Outlook
Piper Sandler launches coverage of biotech Climb Bio with an Overweight rating and $23 price target, highlighting its promising pipeline and key catalysts expected in 2026.
/ 899 items
#Healthcare↓
Moderna Surpasses Q4 Revenue Expectations Despite Vaccine Hurdles
Moderna reported $678M in fourth-quarter sales, beating Wall Street forecasts, while facing FDA rejection on its flu shot. The company eyes 10% growth in 2026 amid cost cuts and new deals.
BridgeBio's Breakthrough: Oral Drug Succeeds in Dwarfism Study
BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.
Seres Therapeutics Shifts Focus to Promising New Programs
Seres Therapeutics announces pauses in some studies, workforce cuts, and a new emphasis on treatments for inflammatory and immune diseases like ulcerative colitis, aiming to extend cash through 2026.
Raymond James Upgrades Oscar Health to Outperform – Sees Big Upside
Raymond James upgrades Oscar Health stock to Outperform with $18 target, calling valuations attractive as margins improve in ACA market and forward outlook strengthens.
FDA Approves Novocure's Optune Pax: A New Hope for Pancreatic Cancer Patients
Novocure's Optune Pax wearable device wins FDA approval for locally advanced pancreatic cancer with gemcitabine + nab-paclitaxel. Phase 3 trial shows improved survival and delayed pain progression.